EP1720885A1 - Verfahren zur herstellung von olanzapin in einer polymorphen form i - Google Patents

Verfahren zur herstellung von olanzapin in einer polymorphen form i

Info

Publication number
EP1720885A1
EP1720885A1 EP05701231A EP05701231A EP1720885A1 EP 1720885 A1 EP1720885 A1 EP 1720885A1 EP 05701231 A EP05701231 A EP 05701231A EP 05701231 A EP05701231 A EP 05701231A EP 1720885 A1 EP1720885 A1 EP 1720885A1
Authority
EP
European Patent Office
Prior art keywords
olanzapine
acetate
acetic acid
solvent
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05701231A
Other languages
English (en)
French (fr)
Inventor
Rolf Keltjens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of EP1720885A1 publication Critical patent/EP1720885A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to a new method of making olanzapine in the crystalline Form I and to the new salt or adduct useful therein.
  • Olanzapine is a pharmaceutically useful compound. In medical treatments, it is useful as an antipsychotic agent, particularly for the treatment of schizophrenia; it acts as serotonin (5- HT2) and dopamine (D1/D2) receptor antagonist with anticholinergic activity.
  • the marketed final forms include coated tablets and quick dissolvable tablets.
  • the single tablet comprises from 2.5 to 20 mg of olanzapine
  • Olanzapine is an amine and may form acid addition salts.
  • US 5,229,382 does not refer to any specific polymorphic crystalline form of olanzapine.
  • US 5,229,382 also describes a synthetic method for making crude olanzapine, wherein "des-methylpiperazine olanzapine" intermediate (as the HCl-salt usually) reacts with N-methylpiperazine in DMSO/toluene at enhanced temperature to make olanzapine.
  • the reaction is illustrated by the following equation:
  • EP 733635/US 5,736,541 disclose Form II olanzapine which is characterized by a main X-ray powder diffraction peak of d-value 10.26 A. This form has been prepared by crystallizing "technical grade" olanzapine (a product from the above synthesis) from ethyl acetate. This form appears to be more stable than the Form I, but it is convertible to the said
  • Form I Similarly as Form I, the Form II is an anhydrate.
  • US 6348458 (WO 01/47933) discloses other crystalline polymorphic forms of olanzapine, namely Form III, Form IV and Form V. More recently, WO 03/091260 discloses
  • Form VI olanzapine US appl. 2002-0086993 discloses a poymorphic form designated as form X.
  • the EP 828494 calls as Olanzapine Form I a product that is identical with Olanzapine Form II of the above definition
  • the "Form I olanzapine" is defined within this invention as the solid state form of anhydrous olanzapine base which is characterized by a main peak on the X-ray powder diffraction spectrum of d- value 9.9463 A.
  • the full diffraction pattern of the Form I has been disclosed in EP 733635.
  • WO 02/18390 indicates that, upon repetition of the disclosed process, the product of US '382 does not correspond to the Form I, but it is rather a Form II olanzapine (see above for definition) after the crystallization from acetonitrile, or a hydrated olanzapine prior said crystallization.
  • the Form I complying with the above definition was actually prepared in WO 02/18390 by recrystallization of olanzapine Form II or a hydrate of olanzapine from dichloromethane, followed by drying of the wet product at 60-70°C.
  • the product of crystallization is a dichloromethane solvate of olanzapine, which liberates dichloromethane under the conditions of drying and yields the Form I.
  • Reutzel-Edens et al. ( Crystal Growth and Design, 2003, vol. 3, No. 6, 897-907) studied various solid state forms of anhydrous and hydrated forms of olanzapine. They have found out that while it is possible to prepare pure Olanzapine form II by a direct crystallization from various solvents (please note that such form is designed as " Form I" in that article), it is impossible to prepare Olanzapine Form I (designed as "Form II” in that article) in such a way.
  • the Form I is obtainable only by a desolvation of various olanzapine solvates (methanol, dichloromethane and/or chloroform solvates) and such a product is admixed with various other forms of olanzapine. No conditions were identified that would yield pure form I.
  • WO 03/97650 purports to prepare essentially pure Olanzapine Form I by a desolvation of various olanzapine solvates. However, when looking on the published X-ray diffraction pattern of the product, the product is not the Olanzapine form I as above-defined. Essentially pure Olanzapine Form I was prepared and characterised in WO 03/101997, employing a complicated purification and precipitation process.
  • WO 04/006933 attempts to prepare Olanzapine Form I by a desolvation of various solvates and mixed solvates.
  • the Form I olanzapine is still an important product so that an improvement in making it is desirable.
  • the present invention relates to an olanzapine acetate and the uses thereof in forming olanzapine.
  • a first aspect of the invention relates to providing an olanzapine acetate, in any form including dissolved in a solvent, but preferably in solid, especially crystalline form.
  • olanzapine acetate means the salt, adduct, or complex of olanzapine and acetic acid in substantially equimolar amounts.
  • a preferred substance of the invention is a crystalline compound comprising substantially equimolar amounts of olanzapine and acetic acid, and/or the respective ions thereof.
  • Another aspect of the invention relates to a process of making olanzapine acetate in solid form, which comprises contacting a source of olanzapine with acetic acid in a solvent, and precipitating the olanzapine acetate from the solvent.
  • the solvent is acetone.
  • the "source of olanzapine” includes olanzapine base, in any solid state form or as a solvate, or a reaction mixture comprising olanzapine base as the product of a chemical reaction.
  • a further aspect of the invention relates to a process for making olanzapine Form I, which comprises heating a solid state olanzapine acetate at a temperature within the range of 50-120°C for a sufficient time to form olanzapine Form I.
  • the heating is preferably under diminished pressure or vacuum or under other means that aid the removal of the liberated acetic acid from the remaining olanzapine such as an inert gas purge.
  • the product of the heating step is olanzapine form I.
  • the process typically provides olanzapine Form I substantially free form other forms of olanzapine, including hydrates and solvates.
  • An additional aspect of the invention relates to a process of purifying of olanzapine, which comprises converting olanzapine into olanzapine acetate, isolating said olanzapine acetate and converting the olanzapine acetate to olanzapine.
  • the conversion can be by heating to form olanzapine Form I or by reaction ⁇ vith base to form olanzapine with optional further precipitation to a desired solid form.
  • Figure 1 is an x-ray powder diffraction pattern (XRPD) corresponding to the olanzapine acetate of example 3.
  • Figure 2 is an x-ray powder diffraction pattern (XRPD) corresponding to the olanzapine Form I produced in example 4.
  • the present invention is based on the discovery that olanzapine acetate can be converted to olanzapine Form I by heating. Surprisingly, not only is the thermal degradation into olanzapine Form I possible, but generally a substantially pure Form I is obtained, free of the other olanzapine forms.
  • the olanzapine acetate in solid state is a particulate material, with no or minimal tendency of reversible absorption of water from the environment, and with good handling properties. It is sufficiently stable under normal conditions of temperature and moisture. In particular, the solid material may exhibit substantially white to yellow color. Typically, it exhibits an X-ray powder diffractogram as shown in fig. 1.
  • Olanzapine acetate of the present invention is presumed to be a salt.
  • the acetic acid being a weak acid, reacts with essentially only one of the basic nitrogens in the olanzapine ring structure to form a molar ratio of olanzapine (or ion thereof) to acetic acid (or ion thereof) of about 1 : 1 +/- 0.1.
  • Its chemical formula can be represented as:
  • the acetic acid is removable by heating to form the olanzapine base in Form I.
  • the acetate salt converts to a solvate and then undergoes desolvation, or, is not a true salt but is an adduct, complex, solvate, etc. is not yet entirely clear.
  • olanzapine acetate as used in the present invention embraces traditional salts of olanzapine and acetic acid as well as adducts, complexes, solvates, etc.
  • the ability of the acetate to thermally convert to olanzapine base is apparently unique.
  • the solid state olanzapine acetate of the present invention is a compound that can yield olanzapine base after thermal treatment. Under typical conditions, solid state, especially crystalline olanzapine acetate is placed in the heated vessel, without employing any solvent or catalyst, and is heated to a temperature between 50°C and 120°C, preferably between about 70-100°C, for a sufficient time to substantially remove all the acetic acid from the vessel.
  • the liberated acetic acid is advantageously removed from the vessel with the aid of diminished pressure, especially vacuum or by a stream of inert gas, the first being preferred. If necessary (particularly from the safety and ecology aspects), the liberated gaseous acetic acid removed from the vessel may be trapped into a solvent, adsorbed on a column with a suitable adsorbent, condensed by cooling in a cooling trap, or neutralized in a washer filled by a solution of appropriate base.
  • the product of the heating (and presumed thermal decomposition) of olanzapine acetate is Olanzapine Form I. Such form, as known from documents of the prior art, was made so far only by drying the dichloromethane solvate of olanzapine.
  • the decomposition temperature is lower than the transition temperature at which the Form I is converted into Form II (such transition temperature is about 125°C according to the article, crystal growth & design, 2003, 3, 897-907)
  • the produced olanzapine Form I is typically substantially free from other solid state forms, hydrates and /or solvates.
  • the content of the Form I is higher than 99%.
  • the yield of olanzapine Form I after thermal conversion of olanzapine acetate is substantially quantitative.
  • a method of making the olanzapine acetate in solid state is contacting a source of olanzapine with acetic acid in a solvent, and precipitating the olanzapine acetate from said solvent.
  • the aqueous solubility of olanzapine acetate limits the number of useful solvent systems. Preferably, such solvent system should not comprise water hut this does not preclude using mixtures of nonaqueous solvents with water in the process.
  • Suitable solvents comprise C1-C6 aliphatic ketones, C1-C6 ethers (incl. cyclic ethers) or C1-C6 esters.
  • the most useful solvent in making the olanzapine acetate is acetone.
  • Olanzapine base and sources thereof are generally sufficiently soluble therein as well as acetic acid, while olanzapine acetate is only slightly soluble in acetone.
  • acetone is a good solvent for affording contacting of the olanzapine base material and acetic acid as well as for facilitating the subsequent precipitation or crystallization of the olanzapine acetate.
  • Other useful solvents are ethylacetate and tetrahydrofuran.
  • the solubility of starting materials in the solvent may be enhanced by raising the temperature of the reaction mixture, so that the salt forming reaction may proceed at a temperature from ambient to a boiling point of the solvent.
  • the so formed solution of the salt may be treated with a suitable adsorption material such as activated charcoal, to remove contaminants.
  • a suitable adsorption material such as activated charcoal
  • the solubility of the salt product in the solvent system may be, accordingly, decreased by cooling the reaction mixture.
  • precipitation from the solvent is preferred to be spontaneous at the temperature of salt formation or to proceed after cooling.
  • the precipitation may be forced by reducing the volume of the solvent, seeding, adding a contrasolvent or combination of these techniques. Any grade or form of olanzapine is useful in the above process for making olanzapine acetate.
  • the "technical grade" olanzapine (this material comprises also solvates of olanzapine with various solvents), Olanzapine Form II, Olanzapine hydrate etc.
  • the olanzapine acetate may be also prepared by a direct synthesis of the olanzapine moiety.
  • the des-methyl olanzapine (3) may be methylated by formic acid formaldehyde (Eschweiler-Clarke reaction) under the equation (3) (1) and the reaction mixture comprising olanzapine is treated with the acetic acid, under conditions that olanzapine salt, in his case olanzapine acetate, precipitates from the mixture.
  • the "des-piperazine olanzapine (2)" may be treated with N-methylpiperazine to yield olanzapine within a reaction mixture, as shown above, and such reaction mixture, after necessary elaboration, is treated with acetic acid under conditions of precipitation of the olanzapine acetate from it.
  • olanzapine acetate represents a suitable tool for purifying olanzapine, particularly the technical grade olanzapine.
  • the process generally comprises converting olanzapine into olanzapine acetate, isolating the olanzapine acetate and converting the olanzapine acetate to olanzapine.
  • a preferred process comprises the step of transforming technical grade olanzapine base into olanzapine acetate in a non-aqueous solvent.
  • the technical grade olanzapine is efficiently purified from contaminants. This process may remove contaminants which are hardly removable by crystallization and generally avoids enhanced temperatures (a source of decomposition) that are required in routine crystallization procedures.
  • the conversion of the olanzapine acetate back to olanzapine base can also be arranged by reaction with a base in solvent.
  • the free base of olanzapine may precipitate or be further processed.
  • various forms of olanzapine in improved purity may be obtained. For instance, as shown above, thermal decomposition of olanzapine acetate will yield olanzapine form I. Reaction of the olanzapine acetate with the base in an aqueous medium generally yields olanzapine hydrate.
  • Reaction of olanzapine acetate with a base in an alcoholic solvent generally yields olanzapine alcoholates, i.e., methanolate or isopropanolate.
  • olanzapine alcoholates i.e., methanolate or isopropanolate.
  • Example 1 Olanzapine acetate To a solution of 5.0 g of olanzapine base in 150 ml acetone was added slowly 1.06 g of acetic acid at room temperature and the mixture was stirred overnight at 4C. The crystals were isolated by filtration, washed with 20 ml acetone and 20 ml of ether and dried overnight at 40C in vacuo. Yield: 3.32g (56%)
  • Example 2 Olanzapine acetate To 10.0 g olanzapine free base dissolved in 200 ml acetone was added slowly 3.85 g acetic acid at room temperature. The resulting mixture was stirred overnight at 4 °C, and the crystals were isolated by filtration, washes with diethyl ether and dried overnight at 40 °C in vacuum.
  • Example 3 Olanzapine acetate To a clear solution of 1.0 g of olanzapine free base in 40 ml ethyl acetate was added at room temperature 0.38 g acetic acid. The resulting clear mixture was seeded and subsequently stirred overnight at 4 °C. The crystals were isolated by filtration and dried overnight at 40 °C in vacuo. Isolated yield: 0.94 gram (79%) The XRPD is shown in fig. 1.
  • Example 4 Olanzapine Form I In a 10 ml flask, 0.5 g of olanzapine acetate was stored at 65-70 °C in vacuo to remove the acetic acid.
  • Portion 2 To portion 2, 50 ml water were added and the aqueous layer was extracted three times with

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP05701231A 2004-01-27 2005-01-26 Verfahren zur herstellung von olanzapin in einer polymorphen form i Withdrawn EP1720885A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53912004P 2004-01-27 2004-01-27
US56222504P 2004-04-15 2004-04-15
US56960704P 2004-05-11 2004-05-11
PCT/EP2005/000834 WO2005070937A1 (en) 2004-01-27 2005-01-26 A process for making olanzapine in a polymorph form i

Publications (1)

Publication Number Publication Date
EP1720885A1 true EP1720885A1 (de) 2006-11-15

Family

ID=34812083

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05707056A Withdrawn EP1711503A1 (de) 2004-01-27 2005-01-26 Synthese von olanzapin und zwischenprodukten davon
EP05701231A Withdrawn EP1720885A1 (de) 2004-01-27 2005-01-26 Verfahren zur herstellung von olanzapin in einer polymorphen form i

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05707056A Withdrawn EP1711503A1 (de) 2004-01-27 2005-01-26 Synthese von olanzapin und zwischenprodukten davon

Country Status (3)

Country Link
EP (2) EP1711503A1 (de)
AR (2) AR047460A1 (de)
WO (2) WO2005070939A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
PL377084A1 (pl) * 2005-09-15 2007-03-19 Koźluk Tomasz Nobilus Ent Nowe związki olanzapiny i sposób ich wytwarzania
WO2007096895A1 (en) * 2006-02-27 2007-08-30 Lee Pharma Limited Preparation of anhydrous olanzapine of form-1
JP6085900B2 (ja) * 2012-04-02 2017-03-01 大日本印刷株式会社 オランザピンの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
JP2001517684A (ja) * 1997-09-30 2001-10-09 イーライ・リリー・アンド・カンパニー 性機能不全を処置するための方法
DE60019461T2 (de) * 1999-12-28 2005-09-22 Cipla Ltd., Bombay Neue polymorphe formen von olanzapin
SK2502003A3 (en) * 2000-08-31 2004-03-02 Reddys Lab Ltd Dr Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
ATE500258T1 (de) * 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
PL199016B1 (pl) * 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005070937A1 *

Also Published As

Publication number Publication date
AR047461A1 (es) 2006-01-18
WO2005070937A1 (en) 2005-08-04
EP1711503A1 (de) 2006-10-18
WO2005070939A1 (en) 2005-08-04
AR047460A1 (es) 2006-01-18

Similar Documents

Publication Publication Date Title
US8202867B2 (en) Methods of using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide
AU2008355336B2 (en) Crystalline form of tenofovir disoproxil and a process for its preparation
IE59901B1 (en) Piperidine derivative, its preparation, and its use as medicament
WO2012150538A1 (en) Crystalline salts of asenapine
EP1656381B1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
US20050272720A1 (en) Process for making olanzapine Form I
EP1651646A1 (de) Neues verfahren zur herstellung von (+)-(s)-clopidogrelbisulfat form-i
WO1999058541A2 (en) Improvements in macrolide production
MXPA03003459A (es) Base venlafaxina cristalina y polimorfos novedosos de clorhidrato de venlafaxina, procesos para su preparacion.
CA2481703A1 (en) Process for preparing granisetron
EP1720885A1 (de) Verfahren zur herstellung von olanzapin in einer polymorphen form i
KR20090084950A (ko) 결정형 칸데사르탄 실렉세틸 제조 방법
CA2615345A1 (en) Crystalline form of rabeprazole sodium
NO317997B1 (no) Fremgangsmate for fremstilling av et naftyridinkarboksylsyrederivat (metansulfonat-sesquihydrat)
EP1674463A1 (de) Rabeprazol-Natriumsalz im kristallines Hydrat Form
TWI295993B (en) Mixed solvate of olanapine, method for preparing it and method for preparing form i of olanzapine therefrom
WO2008130534A1 (en) Crystalline forms of topotecan hydrochloride and processes for making the same
EP1968983B1 (de) Verfahren zur herstellung eines gemischten olanzapinsolvats
CA2372236A1 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo¬2,2,2|oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists
WO2006025065A1 (en) A process for the preparation of anhydrous olanzopine hydrochloride of form-1
CA2577406A1 (en) Process for the production of levorphanol and related compounds
EP1318146B1 (de) Verfahren zur produktion von pyrimidinderivaten und geeignete zwischenprodukte
WO2007016208A2 (en) 1,2-benzisoxazole-3-methane-sulfonic acid ammonium salt
KR20110081382A (ko) 결정성 아데포비어 디피복실 술폰산염 무수물, 그 제조방법 및 이를 포함하는 약제학적 조성물
SI21233A (sl) Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090803

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090801